Phase 2 study of all ‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma

This study is registered at ClinicalTrials.gov (NCT02 046070).

Source: British Journal of Haematology - November 20, 2018 Category: Hematology Authors: Shaji K. Kumar, Norbert Grzasko, Sosana Delimpasi, Wieslaw W. Jedrzejczak, Sebastian Grosicki, Marie ‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A. Dimopoulos Tags: Research Paper Source Type: research